Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.

J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

2.

A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K, Rademeyer C, Gray GE, Williamson C, Stamatatos L, Seaman MS, Korber BT, Chen B, Barouch DH.

J Virol. 2015 Mar;89(5):2507-19. doi: 10.1128/JVI.03331-14. Epub 2014 Dec 24.

3.

A global approach to HIV-1 vaccine development.

Stephenson KE, Barouch DH.

Immunol Rev. 2013 Jul;254(1):295-304. doi: 10.1111/imr.12073. Review.

4.

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD.

Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.

5.

Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Lifson JD, Haigwood NL.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007310. doi: 10.1101/cshperspect.a007310.

6.

Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Matsuo K, Yasutomi Y.

Tuberc Res Treat. 2011;2011:574591. doi: 10.1155/2011/574591. Epub 2011 May 24.

7.

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response.

Cortez V, Odem-Davis K, McClelland RS, Jaoko W, Overbaugh J.

PLoS Pathog. 2012;8(3):e1002611. doi: 10.1371/journal.ppat.1002611. Epub 2012 Mar 29.

8.

Vaccine design for CD8 T lymphocyte responses.

Koup RA, Douek DC.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007252. doi: 10.1101/cshperspect.a007252. Review.

9.

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

McBurney SP, Landucci G, Forthal DN, Ross TM.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72. doi: 10.1089/AID.2011.0351. Epub 2012 Mar 21.

10.

Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection.

Lietz R, Bayer W, Ontikatze T, Johrden L, Tenbusch M, Storcksdieck Genannt Bonsmann M, Uberla K, Dittmer U, Wildner O.

J Virol. 2012 Feb;86(3):1706-16. doi: 10.1128/JVI.06244-11. Epub 2011 Nov 16.

11.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network..

PLoS One. 2011;6(8):e21225. doi: 10.1371/journal.pone.0021225. Epub 2011 Aug 3.

12.

Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.

Flatz L, Roychoudhuri R, Honda M, Filali-Mouhim A, Goulet JP, Kettaf N, Lin M, Roederer M, Haddad EK, Sékaly RP, Nabel GJ.

Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5724-9. doi: 10.1073/pnas.1013084108. Epub 2011 Mar 21.

13.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team..

AIDS Res Hum Retroviruses. 2010 Nov 23. [Epub ahead of print]

14.

Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.

Sun Y, Santra S, Buzby AP, Mascola JR, Nabel GJ, Letvin NL.

Virology. 2010 Oct 10;406(1):48-55. doi: 10.1016/j.virol.2010.07.004. Epub 2010 Jul 27.

15.

Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Cerutti N, Mendelow BV, Napier GB, Papathanasopoulos MA, Killick M, Khati M, Stevens W, Capovilla A.

J Biol Chem. 2010 Aug 13;285(33):25743-52. doi: 10.1074/jbc.M110.144121. Epub 2010 Jun 10.

16.

Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.

Weaver EA, Camacho ZT, Gao F.

AIDS Res Hum Retroviruses. 2010 May;26(5):577-84. doi: 10.1089/aid.2009.0258.

17.

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Brown SA, Surman SL, Sealy R, Jones BG, Slobod KS, Branum K, Lockey TD, Howlett N, Freiden P, Flynn P, Hurwitz JL.

Viruses. 2010 Feb 1;2(2):435-467.

18.

Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Choi SY, Suh YS, Cho JH, Jin HT, Chang J, Sung YC.

Immune Netw. 2009 Oct;9(5):169-78. doi: 10.4110/in.2009.9.5.169. Epub 2009 Oct 30.

19.

Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.

Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD.

Nat Med. 2010 Mar;16(3):339-45. doi: 10.1038/nm.2104. Epub 2010 Feb 7.

20.

HIV-1 vaccine development after STEP.

Barouch DH, Korber B.

Annu Rev Med. 2010;61:153-67. doi: 10.1146/annurev.med.042508.093728. Review.

Supplemental Content

Support Center